HDG, The pipeline bit did catch my attention. After the wording you posted they have covid-19 in brackets. I don't think it means what it means. Sleven,
HD no argument here I am a HS teacher and we’ve got some real literacy problems and then laziness. You pulled a couple of gems out of there
One item that struck me was the sad page 15. Look at the bar graph and the size of the bars ... Vascepa captures a very small portion of what they’re calling at-risk patients from unproven products. What is Amarin doing to address it?
I wonder how they will do this especially in the US without adding marketing or sales force.
Also the Covid spice on page 20 is the stuff that makes people dream of a runaway stock price but we know the long dreary road of waiting for data to arrive when trials complete. Cheers to upcoming interims.
Re 2021 other - pursue pipeline is a head scratcher... unless it’s that long rumored combo pill with a statin plus Vascepa what was it they called it AMR 102? I find it hard to believe Amarin is about to start acquiring other companies? Or IP of other companies? Now I’m all mixed up. Great nuggets you pulled.
After more clinical data is available, assessments will be advanced regarding potential regulatory and commercial opportunities of VASCEPA/VAZKEPA and COVID- 19 and/or potentially other infectious diseases
News 
Market Data 
Discover 
